Cigna Stock Earnings Reports

Cigna reported a strong Q1 2026: total revenues of $68.5 billion and adjusted EPS of $7.79 (16% YoY growth). Management raised full‑year 2026 adjusted EPS guidance to at least $30.35. Key business takeaways: Evernorth (pharmacy, specialty and care services) delivered solid results overall with Specialty & Care Services growing strongly (pretax adjusted earnings +20%) while Pharmacy Benefit Services (PBS) was in line with expectations but down YoY due to large client renewals and investments to transition to the new rebate‑free PBS model called "Signature." Cigna Healthcare outperformed expectations (pretax adjusted earnings +18% YoY) driven by persistency, disciplined execution and favorable MCR drivers in Q1 (e.g., lower flu volumes, weather deferrals, higher share of bronze exchange enrollees). Strategic portfolio actions announced: planned exit of the individual ACA exchange business at year‑end 2026 and a strategic review of alternatives for eviCore. Management emphasized investment in data, advanced analytics and AI (used to speed workflows, improve predictions and personalize care — not for clinical decision‑making), continued prioritization of specialty and care services, and disciplined capital allocation (debt reduction, share repurchase and dividends). Leadership transition: David Cordani will become Executive Chair and Brian Evanko will become CEO on July 1, with continuity in strategy and intensified focus on AI‑enabled, consumer‑focused health services. Capital and cash flow: operating cash flow was $1.1 billion in Q1; debt‑to‑capital was 42.3% and expected to improve by year‑end. Management reiterated prudence on cost trends while pointing to ongoing opportunities from biosimilar adoption, specialty growth, and Signature adoption, which they expect to scale into 2028.